A Small-Molecule Drug Conjugate Targeting FAP Exhibits Potent Activity in Dogs with Spontaneous Tumors
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Andrea Galbiati und 16 weiteren Autor:innen. Beteiligte Einrichtung: Philochem AG, R&D department, Otelfingen CH-8112, Switzerland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Membrane Proteins, Gelatinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Antibody-drug conjugates have transformed the treatment of cancer, yet their clinical utility can be limited by suboptimal tumor penetration, complex manufacturing, and safety concerns. Replacing antibodies with low-molecular-weight ligands enables the generation of small molecule-drug conjugates with enhanced tumor-targeting performance. Here, we report the results of a proof-of-concept study in canine cancer patients with OncoFAP glidotin, a small molecule-based targeted cytotoxic directed against Fibroblast Activation Protein. OncoFAP glidotin was evaluated in a dose-escalation trial in eight client-owned pet dogs bearing spontaneous FAP-positive tumors. The agent displayed an excellent safety profile, with no severe treatment-related adverse events. Six (75%) patients responded to the therapy. A tumor volume reduction of up to ∼88% in target lesions was observed on whole-body computed tomography, after only 4 weeks of treatment. These findings support further translational development activities of OncoFAP glidotin for both human and veterinary cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Philochem AG, R&D department, Otelfingen CH-8112, Switzerland.
- Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi IT-26900, Italy.
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa 56126, Italy.
- University of Pisa and Azienda Ospedaliero Universitaria Pisana, Department of Translational Research and Advanced Technologies in Medicine and Surgery, Pisa 56126, Italy.
- Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences, Zurich CH-8093, Switzerland.
- Philogen S.p.A, Siena I-53100, Italy.
ORCID-Profile: Andrea Galbiati, Matilde Bocci, Ettore Gilardoni, Samuele Cazzamalli
Zitieren
APA
Galbiati, A., Roccabianca, P., Dell'Aere, S., Bocci, M., Auletta, L., Ferrari, R., Ubiali, A., Gariboldi, E. M., Marsala, E., Faviana, P., Bartoli, F., Zoanni, B., Gilardoni, E., Longo, M., Neri, D., Stefanello, D., & Cazzamalli, S. (2026). A Small-Molecule Drug Conjugate Targeting FAP Exhibits Potent Activity in Dogs with Spontaneous Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00682
Vancouver
Galbiati A, Roccabianca P, Dell'Aere S, Bocci M, Auletta L, Ferrari R, et al. A Small-Molecule Drug Conjugate Targeting FAP Exhibits Potent Activity in Dogs with Spontaneous Tumors. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00682
BibTeX
@article{Galbiati2026,
author = {Galbiati, Andrea and Roccabianca, Paola and Dell'Aere, Silvia and Bocci, Matilde and Auletta, Luigi and Ferrari, Roberta and Ubiali, Alessandra and Gariboldi, Elisa M and Marsala, Emanuele and Faviana, Pinuccia and Bartoli, Francesco and Zoanni, Beatrice and Gilardoni, Ettore and Longo, Maurizio and Neri, Dario and Stefanello, Damiano and Cazzamalli, Samuele},
title = {A Small-Molecule Drug Conjugate Targeting FAP Exhibits Potent Activity in Dogs with Spontaneous Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00682}
}
EUVIMED